ALFA Finder
| Market Cap | ₹1,659.8 CrChemicals Sector |
|---|---|
| Revenue TTM | ₹1,254.2 CrOperating Income |
| P/E Ratio | 14.7xSector 35.1x |
| 1-Year Return | 86.8%Stock Performance |
Key highlights
- EDQM confirms EU GMP compliance for the Vapi manufacturing facility in Gujarat
- Approval covers the production of Dexamethasone under CEP No. 2024-138
- Inspection conducted in February 2026 resulted in Reference Number INSP 2025-052-PO1
- Company reported a 374.3% YoY surge in net profit to ₹55.92 crore in the latest quarter
- Operating margins expanded to 18.6% from 11.3% in the corresponding period last year
Vapi Facility Secures European Quality Seal
Bhageria Industries has received the Attestation of Good Manufacturing Practice from the European Directorate for the Quality of Medicines & HealthCare for its manufacturing plant located at Plot No 6102/10 GIDC IV Phase, Vapi. The audit, conducted from February 4 to February 6, 2026, focused on the production of Dexamethasone under Certificate of Suitability No. 2024-138.
This attestation serves as a formal validation that the facility adheres to the rigorous European Good Manufacturing Practice framework. The receipt of this regulatory approval is a critical milestone, enabling the company to supply Dexamethasone into the European Union and other global markets that recognize EDQM standards.
Operational Strength and Financial Momentum
- Latest quarter revenue reached ₹455.7 crore, marking a 123.0% increase over the previous year.
- Net profit for the quarter ended September 2026 stood at ₹55.92 crore, up 374.3% YoY.
- The company maintains a high promoter holding of 71.85%, reflecting strong internal confidence.
- The Vapi approval follows the October 2025 launch of new Plasticizers and Ethoxylates product lines at Tarapur.
- Operating profit margins have improved to 18.6%, significantly outpacing the 11.3% recorded a year ago.
Strategic Expansion and Renewable Integration
The EDQM approval strengthens Bhageria Industries' position within the Chemicals & Petrochemicals sector as it shifts toward higher-value pharmaceutical intermediates. This move complements the company's diversification into renewable energy, where it is executing a 32 MW solar power project under a 25-year agreement. As of May 2026, 21 MW of this capacity has already been commissioned, with management guiding for annual revenues of ₹22 to ₹25 crore upon full project completion.
Despite an ongoing appeal at the Securities Appellate Tribunal scheduled for early 2027, the company's core operations continue to show significant growth, evidenced by a 142.8% ROC21 technical indicator.
| Date | Announcement | Amount |
|---|---|---|
| 19 Mar 2026 | Receipt of Conditional Restart Directions from MPCB for Sulphonation section of H-Acid manufacturing unit at Tarapur facilitySource: NSE filing | – |
| 08 Oct 2025 | Launch of new Plasticizers & Ethoxylates product line following receipt of Consent to Operate from MPCB for Tarapur facilitySource: NSE filing | – |
What to watch next
- Final disposal hearing of the SEBI adjudication appeal at SAT on January 5, 2027
- Commissioning of the remaining 11 MW capacity for the MSKVY 2.0 solar power project
- Commercial export ramp-up of Dexamethasone following the new EU GMP certification
- Next quarterly financial results announcement scheduled for early 2027
| Share price | ₹380.3 |
|---|---|
| Market capitalisation | ₹1,659.79 Cr |
| Revenue (annual) | ₹873.96 Cr |
| Net profit (annual) | ₹46.08 Cr |
| Revenue (latest quarter) | ₹455.70 Cr+59.10% vs previous quarter |
| Net profit (latest quarter) | ₹55.92 Cr+63.75% vs previous quarter |
| P/E (TTM) | 14.68×Sector 35.14× |
| Promoter holding | 71.85%+0.08% QoQ |
| FII holding | 0.47%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Bhageria Industries Limited announcing the receipt of EDQM attestation for its Vapi facility. Market figures from a third-party data provider.
